A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

Martin Farlow, Ravi Anand, John Messina, Richard Hartman, Jeffrey Veach

Research output: Contribution to journalArticle

289 Scopus citations

Abstract

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish (US)
Pages (from-to)236-241
Number of pages6
JournalEuropean Neurology
Volume44
Issue number4
DOIs
StatePublished - Jan 1 2000

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitor
  • Clinical trial
  • Rivastigmine

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this